Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s stock ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

With so many weight loss medications on the market, it’s easy to feel overwhelmed by the options. From brand-name heavy ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...

Ozempic and Wegovy, made by Novo, are on track to become the world’s top-selling drugs by 2025. Yet in 2024, ‘Wegovy Wednesday’ had already become one of the biggest weight-loss trends to sweep the ...